Summary

The first European League Against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biologic disease-modifying antirheumatic drugs (DMARDs) were published in 2010 [Smolen JS et al. Ann Rheum Dis 2010]. A task force proposed updated recommendations in April 2013. This article discusses the the 2013 preliminary recommendations. which are based on three systemic literature reviews on the following topics: 1) DMARDs; 2) biologic DMARDs; and 3) safety issues.